The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early tumor marker decrease to predict the efficacy of combination therapy with lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC).
 
Hui-Chuan Sun
Speakers' Bureau - Bayer; Eisai; Hengrui Pharmaceutical; MSD
 
Xiao-Dong Zhu
Speakers' Bureau - Eisai; Hengrui Pharmaceutical; MSD
 
Cheng Huang
No Relationships to Disclose
 
Ying-Hao Shen
No Relationships to Disclose
 
Ning-Ling Ge
No Relationships to Disclose
 
Jin-Jin Zhu
No Relationships to Disclose
 
Bin Xu
No Relationships to Disclose
 
Yi Chen
No Relationships to Disclose
 
Mei-Ling Li
No Relationships to Disclose
 
Jian Zhou
No Relationships to Disclose
 
Jia Fan
No Relationships to Disclose